Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face

Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products